This article was originally published in The Tan Sheet
Bellevue, Wash.-based firm has submitted an investigational new drug application with FDA in advance of conducting studies on extended-release ibuprofen in humans, the firm announces. The trial is slated to begin in early 2005, with an NDA submission planned for the summer, SCOLR adds. The firm initially aimed to begin human trials in Canada this fall (1"The Tan Sheet" Aug. 2, 2004, p. 12)...
You may also be interested in...
SCOLR Pharma plans to file an NDA in summer 2005 for CDT extended-release 12-hour ibuprofen tablets, the firm announced July 26
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Blueprint Medicines' Ayvakyt for treating unresectable or metastatic gastrointestinal stromal tumors. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.